List of Figures

Figure 1.1.1. Schematic representation of the circular HPV DNA genome representing early and late genes. ................................................................. 4

Figure 1.1.2. Events associated with transformation of normal cervical cells to cancerous phenotype after HPV infection. .................................................. 5

Figure 1.1.3. Mechanisms involved in HPV E6 and E7 mediated cervical cancer development. ......................................................................................... 9

Figure 1.1.4. Molecular mechanisms modulated in cervical cancer. ..................... 14

Figure 1.1.5. Risk factors for cervical cancer development. ............................... 15

Figure 1.1.6. Complementary and Alternative Therapies .................................. 17

Figure 1.2.1. Classification of Fatty acids. .......................................................... 19

Figure 1.2.2. Structure of Alpha Linolenic Acid. ............................................... 22

Figure 1.2.3. Biosynthesis of omega-6 and omega-3 PUFAs. ............................ 24

Figure 2.1. ALA altered the viability of the cervical cancer cell lines. ............... 49

Figure 2.2. ALA regulated the growth kinetics of cervical cancer cells. ............ 51

Figure 2.3. ALA reduced nitric oxide levels in cervical cancer cell lines. .......... 52

Figure 2.4. ALA reduced iNOS levels in cervical cancer cell lines. ................... 53

Figure 2.5. ALA increased lipid peroxidation in cervical cancer cells. ............... 54

Figure 2.6. ALA induced apoptosis in cervical cancer cells. ............................. 55

Figure 3.1. ALA reduced cell migration and decreased the expression of MMPs and VEGF proteins. ........................................................................... 65

Figure 3.2. ALA regulated NFκB and COX-2 expression in cervical cancer cells. 66

Figure 3.3. ALA reduced the expression of phosphoryled MAPKs and c-Jun......... 67

Figure 3.4. ALA modulated the expression of tumour regulatory proteins. .......... 68

Figure 3.5. ALA reduced the expression of viral oncoproteins E6 and E7 ............ 69

Figure 4.1. Combination of ALA and cisplatin reduced the viability of cancer cells. 83

Figure 4.2. Flax Oil reduced tumor growth in TC1 mouse melanoma model....... 85

Figure 4.3. Effect of flax oil, cisplatin and combination of cisplatin with FO on expression of HPV E6 and E7 of TC1 induced Tumor mice model............. 88

Figure 4.4. Flax oil, cisplatin and Cis+FO modulated Th1/Th2 cytokine levels. ....... 90

Figure 4.5. Effect of Flax oil, cisplatin and Cis+FO on plasma antioxidant levels in mice ............................................................................................................. 91
Figure 4.6. Effect of Flax oil, cisplatin and Cis+FO on TBARs levels in the tumor tissue and liver tissues of mice.

Figure 5.1. Structure of Cinnamaldehyde

Figure 5.2. Structure of Curcumin

Figure 5.3. Structure of andrographolide

Figure 5.4. Combination andrographolide and 80µM of ALA alters cell growth
List of Tables

Table 1.1.1. Burden of cervical cancer due to HPV infection in India .......................2
Table 1.1.2. Functions of HPV oncoproteins ...............................................................6
Table 1.2.1. Fatty acid intake in population ..................................................................25
Table 1.2.2. Anticancer activity of ALA in different cancers ........................................28
Table 1.3.1. Medicinal plants/herbal bioactives that target various signaling pathways in cervical cancer ...........................................................................................................34
Table 3.1. Relative Fatty acid composition of SiHa treated with ALA (0-80 µM) .... 71
Table 3.2. Relative Fatty acid composition of HeLa treated with ALA (0-80 µM) ... 72
Table 4.1. IC$_{50}$ value of cisplatin in combination with ALA in TC1, SiHa and HeLa83
Table 4.2. Body weights of C57BL/6J mice .................................................................86
Table 4.3. Relative organ weights of C57BL/6J mice ..................................................87
Table 4.4. Relative Fatty acid composition of diet and flax oil fed to animals during experiment ..........................................................................................................................95
Table 4.5. Relative Fatty acid composition in tumor cells treated with Cisplatin, FO 200 and 400 and Cis+FO ....................................................................................96
Table 5.1. Percent viability of SiHa cells treated with ALA, Cinnamaldehyde or their combinations ..........................................................107
Table 5.2. Percent viability of HeLa cells treated with either ALA, Cinnamaldehyde or their combinations ...................................................107
Table 5.3. Percent viability of SiHa cells treated with either ALA, Curcumin or their combinations .................................................................................108
Table 5.4. Percent viability of HeLa cells treated with ALA, Curcumin and their combinations ..................................................................................109
Table 5.5. Percent viability of SiHa cells treated with ALA, andrographolide and their combinations .................................................................110
Table 5.6. Percent viability of HeLa cells treated with ALA, andrographolide and their combinations .................................................................111
Table 5.7. Percent viability of HaCaT cells treated with ALA, andrographolide and their combinations .................................................................111